134 related articles for article (PubMed ID: 31118140)
1. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Liu JF; Gray KP; Wright AA; Campos S; Konstantinopoulos PA; Peralta A; MacNeill K; Morrissey S; Whalen C; Dillon D; Matulonis UA
Gynecol Oncol; 2019 Jul; 154(1):95-101. PubMed ID: 31118140
[TBL] [Abstract][Full Text] [Related]
2. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
Westin SN; Sill MW; Coleman RL; Waggoner S; Moore KN; Mathews CA; Martin LP; Modesitt SC; Lee S; Ju Z; Mills GB; Schilder RJ; Fracasso PM; Birrer MJ; Aghajanian C
Gynecol Oncol; 2019 Dec; 155(3):420-428. PubMed ID: 31623857
[TBL] [Abstract][Full Text] [Related]
3. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.
Ragon BK; Odenike O; Baer MR; Stock W; Borthakur G; Patel K; Han L; Chen H; Ma H; Joseph L; Zhao Y; Baggerly K; Konopleva M; Jain N
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):431-440.e13. PubMed ID: 31056348
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
Tolcher AW; Kurzrock R; Valero V; Gonzalez R; Heist RS; Tan AR; Means-Powell J; Werner TL; Becerra C; Wang C; Leonowens C; Kalyana-Sundaram S; Kleha JF; Gauvin J; D'Amelio AM; Ellis C; Ibrahim N; Yan L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):673-683. PubMed ID: 32062691
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
6. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Bedard PL; Tabernero J; Janku F; Wainberg ZA; Paz-Ares L; Vansteenkiste J; Van Cutsem E; Pérez-García J; Stathis A; Britten CD; Le N; Carter K; Demanse D; Csonka D; Peters M; Zubel A; Nauwelaerts H; Sessa C
Clin Cancer Res; 2015 Feb; 21(4):730-8. PubMed ID: 25500057
[TBL] [Abstract][Full Text] [Related]
7. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Aghajanian C; Bell-McGuinn KM; Burris HA; Siu LL; Stayner LA; Wheler JJ; Hong DS; Kurkjian C; Pant S; Santiago-Walker A; Gauvin JL; Antal JM; Opalinska JB; Morris SR; Infante JR
Invest New Drugs; 2018 Dec; 36(6):1016-1025. PubMed ID: 29611022
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.
Subbiah V; Meyer C; Zinner R; Meric-Bernstam F; Zahurak ML; O'Connor A; Roszik J; Shaw K; Ludwig JA; Kurzrock R; Azad NA
Clin Cancer Res; 2017 Aug; 23(15):4027-4034. PubMed ID: 28377484
[No Abstract] [Full Text] [Related]
9. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
10. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
11. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Shroff RT; Yarchoan M; O'Connor A; Gallagher D; Zahurak ML; Rosner G; Ohaji C; Sartorius-Mergenthaler S; Parkinson R; Subbiah V; Zinner R; Azad NS
Br J Cancer; 2017 May; 116(11):1402-1407. PubMed ID: 28441383
[TBL] [Abstract][Full Text] [Related]
12. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
Algazi AP; Esteve-Puig R; Nosrati A; Hinds B; Hobbs-Muthukumar A; Nandoskar P; Ortiz-Urda S; Chapman PB; Daud A
Pigment Cell Melanoma Res; 2018 Jan; 31(1):110-114. PubMed ID: 28921907
[TBL] [Abstract][Full Text] [Related]
13. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.
Wu C; Williams TM; Robb R; Webb A; Wei L; Chen W; Mikhail S; Ciombor KK; Cardin DB; Timmers C; Krishna SG; Arnold M; Harzman A; Abdel-Misih S; Roychowdhury S; Bekaii-Saab T; Wuthrick E
Clin Cancer Res; 2020 Jul; 26(13):3117-3125. PubMed ID: 32253228
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
Kurzrock R; Ball DW; Zahurak ML; Nelkin BD; Subbiah V; Ahmed S; O'Connor A; Karunsena E; Parkinson RM; Bishop JA; Ha Y; Sharma R; Gocke CD; Zinner R; Rudek MA; Sherman SI; Azad NS
Clin Cancer Res; 2019 Sep; 25(18):5475-5484. PubMed ID: 31186313
[TBL] [Abstract][Full Text] [Related]
15. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
Corcoran RB; Do KT; Kim JE; Cleary JM; Parikh AR; Yeku OO; Xiong N; Weekes CD; Veneris J; Ahronian LG; Mauri G; Tian J; Norden BL; Michel AG; Van Seventer EE; Siravegna G; Camphausen K; Chi G; Fetter IJ; Brugge JS; Chen H; Takebe N; Penson RT; Juric D; Flaherty KT; Sullivan RJ; Clark JW; Heist RS; Matulonis UA; Liu JF; Shapiro GI
Clin Cancer Res; 2024 May; 30(9):1739-1749. PubMed ID: 38456660
[TBL] [Abstract][Full Text] [Related]
17. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.
Cheraghchi-Bashi A; Parker CA; Curry E; Salazar JF; Gungor H; Saleem A; Cunnea P; Rama N; Salinas C; Mills GB; Morris SR; Kumar R; Gabra H; Stronach EA
Oncotarget; 2015 Dec; 6(39):41736-49. PubMed ID: 26497682
[TBL] [Abstract][Full Text] [Related]
18. Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.
Gungor H; Saleem A; Babar S; Dina R; El-Bahrawy MA; Curry E; Rama N; Chen M; Pickford E; Agarwal R; Blagden S; Carme S; Salinas C; Madison S; Krachey E; Santiago-Walker A; Smith DA; Morris SR; Stronach EA; Gabra H
J Nucl Med; 2015 Dec; 56(12):1828-35. PubMed ID: 26429956
[TBL] [Abstract][Full Text] [Related]
19. Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure.
Barbie DA; Spira A; Kelly K; Humeniuk R; Kawashima J; Kong S; Koczywas M
Clin Lung Cancer; 2018 Nov; 19(6):e853-e859. PubMed ID: 30087028
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Huijberts SCFA; van Geel RMJM; van Brummelen EMJ; Opdam FL; Marchetti S; Steeghs N; Pulleman S; Thijssen B; Rosing H; Monkhorst K; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Cancer Chemother Pharmacol; 2020 May; 85(5):917-930. PubMed ID: 32274564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
